Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study - Wikidata - wikimedia - TriplyDB

Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study

Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study

http://www.wikidata.org/entity/Q33395718

about

Advances of gene therapy for primary immunodeficiencies Stem cell transplantation for primary immunodeficiency diseases: the North American experience Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants Actin cytoskeletal defects in immunodeficiency Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.Wiskott-Aldrich syndrome: a comprehensive review.Gene therapy for PIDs: progress, pitfalls and prospects Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors.Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.X-linked thrombocytopenia in three males with normal sized platelets due to novel WAS gene mutations.Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene.Diagnosis and treatment of inherited thrombocytopenias.Assessment of Immature Platelet Fraction in the Diagnosis of Wiskott-Aldrich Syndrome.Current and emerging treatment options for Wiskott-Aldrich syndrome.A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.Exacerbated experimental arthritis in Wiskott-Aldrich syndrome protein deficiency: modulatory role of regulatory B cells Gene therapy for inherited immunodeficiency.Hematopoietic stem cell transplantation for primary immunodeficiencies.Clinical applications of gene therapy for primary immunodeficiencies.Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome.Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma.Gene therapy for Wiskott-Aldrich Syndrome-Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis.In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome.Primary Immune Deficiency Treatment Consortium (PIDTC) report.Gene therapy for primary immune deficiencies: a Canadian perspective.Primary antibody deficiencies.Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review.Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance.The role of dendritic cells in graft-versus-tumor effect Lentiviral vectors for the treatment of primary immunodeficiencies.ICON: the early diagnosis of congenital immunodeficiencies.Gene therapy for primary immunodeficiencies: current status and future prospects.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.

P2860

Q26742031-26CE2226-3869-4153-AB82-CE63CE92445C Q26827162-66CE5E7F-654F-41B4-8BCB-C55B59D52965 Q26853559-18CBA9AE-CF34-44B8-B65D-1DD81D539D15 Q27021852-9EF32F77-E435-4C65-B944-A64373BD54B2 Q28066193-7D63846D-C6D4-4F4F-B938-4FC464281B99 Q33403252-EB726216-6EED-414C-8D81-F2A559211198 Q33406620-4CBB896F-FDC6-4154-926C-E261B944F5E0 Q33406944-13FC1589-9974-422A-8FD0-C8FE3959A20C Q33407443-1F2F4C49-BF7D-4BDE-9FA4-DFDB9A6A297D Q33408529-273B2CBA-C52D-4E7D-BE07-A6E7C5D1DCB8 Q33413888-430B5291-A1E1-4FF4-9AF8-573DC4B733F8 Q33415221-CA52D852-2AE6-41DF-A601-BA89B279563E Q33417294-83510C1E-733B-4447-8D51-B162BDA279A1 Q33418658-005BD027-94AF-48EA-B6C7-5CDAAA09AFCB Q33422383-A5112765-C9F2-4C6E-A8E4-C75CD0C6D8CD Q33423686-1CC5EA83-CAE6-4C1B-B39A-F4D1E3A9E0FC Q33424297-E63D89C9-9253-4A1F-AAFB-4B1A56CAF218 Q33439801-81C11F9E-6BDD-4EE7-BDCA-D775CDB81561 Q34343785-F4E179AF-96BE-48F3-9770-667B142464F3 Q34356904-40F5626E-B732-4168-BAF9-951B5AB56BC8 Q34401676-DDF3C1AE-B3B7-4B65-918A-4C75501E95CC Q34406496-8846C09F-B991-4647-9BE4-7C1750FC5D46 Q34419791-A461F130-DA9E-40E8-A5C1-733ADC3BEB50 Q34630754-0C774EDD-1332-4184-AA28-BCD64E15F274 Q35539617-BA0CC7AF-817E-4730-8A02-93AD7B1712D2 Q35995198-3EA6F90F-2F36-43FA-BF38-329231874279 Q36101320-B344750A-8DCD-4D7F-9C68-0238DA4D7FCE Q36584648-4EA913FA-073A-4A2D-A71B-4E68A075D57C Q37089345-CEC4B668-C742-493A-B5FA-0EBAB658417C Q37089728-0708C530-1899-48EA-9F87-20FEBAA861AC Q37649782-2C00ABCF-1771-4856-A618-26CFECE2C92A Q37668317-2B521BAA-D2DD-44B0-95EE-F2D4AE40B380 Q38114328-3CD488AC-9B35-4F14-B27B-47A22AF1561C Q38119863-5B59EA18-00F5-4F7A-AFD2-A79328B222B4 Q38191280-0D0325BA-20A3-4DAE-BF39-3C5CD308990F Q38193807-5F14DE71-26DD-4074-A007-042A3CF5DBE9 Q38195200-90345835-C67E-41E3-87EB-7F2468DAD1FA Q38195246-E4109B9C-C643-4FC2-8E42-A04CCE182856 Q38213501-E3644B63-DAA5-438F-B5FB-8AE4E8EF5F68 Q38289442-A697527B-48D5-4EF6-BED3-82F55AA38027

P2860

Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study

http://www.wikidata.org/entity/Q33395718

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Long-term outcome and lineage- ...... ernational collaborative study

@ast

Long-term outcome and lineage- ...... ernational collaborative study

@en

type

label

Long-term outcome and lineage- ...... ernational collaborative study

@ast

Long-term outcome and lineage- ...... ernational collaborative study

@en

prefLabel

Long-term outcome and lineage- ...... ernational collaborative study

@ast

Long-term outcome and lineage- ...... ernational collaborative study

@en

P1433

Q33395718-EEEFEF11-6C78-411F-BB69-296AE7B75CD5

P1476

Q33395718-16308E75-DB4A-4E1B-8DAF-D18B6354BFD8

P2093

Q33395718-05E84A1C-9DE1-4FA2-B66A-2CAA3F526DF4

Q33395718-13C3C193-58EC-4999-ABC1-0BB636C3EFC8

Q33395718-1E2AEFFB-B034-44F7-A68F-ADEB4D020C18

Q33395718-1EFEA568-8972-48D1-AD57-3C2E5F6AEF3D

Q33395718-1F64E249-4429-4907-AA66-ED3EF1A94DFF

Q33395718-27A368FB-5EE9-482C-B20B-13BBBAEF6852

Q33395718-2B341C88-D121-4EB1-B4EA-F7CCF181A071

Q33395718-577A207F-94C0-44B3-ADCB-F4164A57AE23

Q33395718-6914A745-D9A3-44AF-901C-2F66370F4301

Q33395718-7FC43006-414E-4AC3-BDEF-A5C6629F0CFE

P2860

Q33395718-10EDCED1-6A0A-4D3F-91C7-6A1D5129DD2B

Q33395718-1CED4A25-3DFB-4578-9E33-2317CE8623C4

Q33395718-2B0D2831-60EE-4766-8151-6C0973365414

Q33395718-2BA5AE51-1DC3-4F2C-A7C4-ECE90A6037B0

Q33395718-4009A2AE-0235-4236-9360-DCF1B33534F1

Q33395718-43417CCB-0EBB-4CA4-91D1-5CE97E54E2C7

Q33395718-5686C498-9DF6-4027-A85E-F76FEED27BDF

Q33395718-5716F9B9-BE58-4CBF-B5C6-4502CC76DFA1

Q33395718-5DB65A3A-2030-4FCB-ACF3-F265B366A7F5

Q33395718-5E14C004-0B84-4461-AB62-482C5E16654F

P304

Q33395718-4A6C2D70-ABC9-4FB0-8848-06088C666F52

P31

Q33395718-8130505A-4F7A-44B1-9E0A-77EF306C2BD5

P356

Q33395718-CA3963ED-9373-4EA5-9193-0753718C14A9

P407

Q33395718-DE5A69AD-5438-4CBF-86B3-4597F6476635

P433

Q33395718-5412BC77-2F70-47F4-A76C-6BEB7BBA9046

P478

Q33395718-C4F8E286-AC8E-48F2-8C56-C7A282CC1F27

P50

Q33395718-46829F7B-2BE0-4E32-A424-40FE6C77CA77

Q33395718-6B4C238C-0ABD-4565-9F85-03A9B5BDE0F2

Q33395718-843EC646-1E93-443A-A89B-D6B38B393BC2

Q33395718-88084216-1281-46EB-9B5B-615B752EC065

Q33395718-8BEC2349-C836-487E-A5AB-395328D051AC

Q33395718-B937A562-BFAA-43D5-8193-E06310656563

Q33395718-CC7837B8-1986-4383-AB29-0DA73D733EE5

P577

Q33395718-3C0A650B-AE0B-4AAA-846E-CA8E23598755

P5875

Q33395718-0EEB5297-EBE5-49F5-8D12-BA1A52E50653

P698

Q33395718-0633D18F-EBFC-4811-A59C-FD551889C555

P921

Q33395718-5CC10B7D-9E84-4E7F-AACA-38DA51BDBB0E

P932

Q33395718-AB0A6BDC-1538-4F77-946C-29C10D90FCD8

P356

BLOOD-2010-11-319376

P1433

P1476

Long-term outcome and lineage- ...... ernational collaborative study

@en

P2093

Adriana Koliski

http://www.w3.org/2001/XMLSchema#string

Andrew J Cant

http://www.w3.org/2001/XMLSchema#string

Ansgar Schulz

http://www.w3.org/2001/XMLSchema#string

Carmem Bonfim

http://www.w3.org/2001/XMLSchema#string

Daniele Moratto

http://www.w3.org/2001/XMLSchema#string

Elie Haddad

http://www.w3.org/2001/XMLSchema#string

Evelina Mazzolari

http://www.w3.org/2001/XMLSchema#string

Fulvio Porta

http://www.w3.org/2001/XMLSchema#string

Hans D Ochs

http://www.w3.org/2001/XMLSchema#string

Jose Zanis Neto

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of a novel gene mutated in Wiskott-Aldrich syndrome

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.

Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients.

Clinical course of patients with WASP gene mutations.

Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation.

X-linked thrombocytopenia and Wiskott-Aldrich syndrome: similar regional assignment but distinct X-inactivation pattern in carriers.

Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment.

Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome.

New insights into the biology of Wiskott-Aldrich syndrome (WAS).

X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.

P304

1675-1684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-11-319376

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Marina Cavazzana-Calvo

Capucine Picard

Adrian J Thrasher

P577

2011-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51207043

http://www.w3.org/2001/XMLSchema#string

P698

21659547

http://www.w3.org/2001/XMLSchema#string

P921

Wiskott-Aldrich syndrome

P932

3156052

http://www.w3.org/2001/XMLSchema#string